SCIENTURE Reports Q3 2026 Results with Approximately 265% Sequential Revenue Growth Driven by the Commercial Launch of REZENOPY™

ملخص مفصل
First Nine Months of 2026 Revenue Increased Approximately 176% Year-Over-Year to $1.65 Million and Gross Profit Increased Approximately 145% to $1.41 Million COMMACK, NY, Nov. 16,…
Q3 2026 Revenue Increased Approximately 113% Year-Over-Year to $1.25 Million
Arbli™ generated approximately $330,000 and $730,000 of Net Product Revenue for Q3 2026 and the first nine months of 2026 respectively
Initial Wholesale Shipments of REZENOPY™ Generated Approximately $925,000 of Net Product Revenue Following Its August 2026 Launch
Q3 2026 Gross Profit Increased Approximately 77.5% Year-Over-Year to $1.02 Million
First Nine Months of 2026 Revenue Increased Approximately 176% Year-Over-Year to $1.65 Million and Gross Profit Increased Approximately 145% to $1.41 Million
COMMACK, NY, Nov. 16, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) ("Scienture" or the "Company"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a business update and reported financial results for the three and nine months ended September 30, 2026.
Third Quarter 2026 and Nine Months Ended September 30, 2026 Financial Highlights
Narasimhan Mani, President, Interim Chief Financial Officer and Co-Chief Executive Officer of Scienture, commented, "Our third-quarter results demonstrate the accelerating commercial momentum of Scienture as we begin generating meaningful revenue from two FDA-approved pharmaceutical products. Revenue increased approximately 265% sequentially to $1.25 million and more than doubled year-over-year. This growth reflects approximately $925,000 of net revenue from initial wholesale shipments of REZENOPY™ following its August launch, alongside continued progress with Arbli™.
Shankar Hariharan, Executive Chairman and Co-Chief Executive Officer of Scienture, stated, "Arbli™ continues to gain commercial traction, while the successful launch of REZENOPY™ has added a second revenue stream and established our presence in the…
مطلع المقال، مقتطف من Yahoo Finance. لقراءة المقال كاملًا، افتحه على موقع الناشر.
يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (finance.yahoo.com)




